The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 526.00
Bid: 526.00
Ask: 527.00
Change: -3.00 (-0.57%)
Spread: 1.00 (0.19%)
Open: 530.00
High: 530.00
Low: 524.00
Prev. Close: 529.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AuM Update

10 Oct 2019 07:00

RNS Number : 3525P
Polar Capital Holdings PLC
10 October 2019
 

10 October 2019

 

Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its quarterly update of its unaudited statement of its Assets under Management ("AuM").

 

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 September 2019 its AuM were £14.3bn compared to £13.8bn at the end of March 2019, an increase of 3% over the period. During the period, AuM increased by £467m which comprised net outflows of £448m offset by an increase of £915m related to market movement and fund performance.

 

AuM movement in six months

to 30 September 2019

Long only

funds

Alternative funds

Total

AUM at 1 April 2019

£12,529m

£1,306m

£13,835m

Net subscriptions / (redemptions)

£(560)m

£112m

£(448)m

Market movement and

performance

£868m

£47m

£915m

Total AuM at 30 September 2019

£12,837m

£1,465m

£14,302m

 

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year.

 

Performance fees

net of staff allocations

Six months to

30 Sept 18

 

 

Year to

31 Mar 19

(year-end)

 

Six months to

30 Sept 19

 

 

Received

 

£5.5m

£24.0m

£3.3m

Accrued but not yet earned in funds with year ends on or before the financial year end

£27.0m

n/a

£0.9m*

Total net performance fee profits

£32.5m

£24.0m

 

£4.2m*

 

 

*the figures are reduced by £2m of net performance fee distributions that relate to prior accounting periods that IFRS require to be deducted from this year's receipts.

 

 

 

As is usual at the time of releasing this update, three months before the crystallisation of performance fees, we disclose the profits that could be due to Polar as a function of the amount of accrued performance fees in our funds as at the end of September. There is no certainty that the fees will be sustained over the next quarter, as performance fee receipts are extremely volatile.

 

Gavin Rochussen, Chief Executive, commented:

 

"The last quarter has been a challenging period with net outflows of £598m following the £150m of net inflows in the previous quarter.

 

"As communicated at the time of releasing our year-end results in June, the Japan team has undergone changes following the departure of the long-standing manager of our Japan Fund. The team is focused on the Japan Value Fund which has compelling performance and will benefit from greater AuM following the imminent merger of the two funds. Net outflows in the six months from the Japan Fund following the communication of the manager departure and fund merger have been £400m. As at 30 September, the Japanese equities team was managing £314m.

 

"In the six months, two long-standing clients redeemed in excess of £500m from two of our highly rated funds, the Polar Capital Technology Fund and the Polar Capital Healthcare Opportunities Fund to take profits and reduce risk in their underlying client portfolios. This has provided the Technology and Healthcare strategies with additional capacity where the demand for their funds is robust.

 

"Notwithstanding the £900m headwind created by the Japan Fund redemptions and the client redemption from Technology and Healthcare, it is reassuring that, despite the economic and political uncertainty over the last six months, we have had net inflows into the majority of our funds including: Global Insurance, UK Value, European Income and Emerging Market and Asia with positive net inflows of £112m into our alternative fund range which includes our Convertibles and UK Absolute products.

 

"While accrued performance fees are materially less than the previous year, fees are volatile, and the position three months ago was more in line with last year. There are still three months to the end of the calendar year when performance fees crystallise. We remain confident that our active fundamental fund strategies will continue to deliver above average returns over the long term for our clients."

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)John Mansell (Executive Director)

Samir Ayub (Finance Director)

 

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Guy Wiehahn

Andrew Buchanan

 

+44 (0)20 7418 8893

 

Camarco

Ed Gascoigne-Pees

Monique Perks

 

 

+44 (0)20 3757 4995

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDMLBATMBJMBAL
Date   Source Headline
26th Apr 202410:33 amRNSForm 8.3 - RENALYTIX PLC
17th Apr 20243:55 pmRNSDirector/PDMR Shareholding
12th Apr 20245:43 pmRNSHolding(s) in Company
11th Apr 20247:00 amRNSAuM Update
9th Apr 20244:01 pmRNSChange of Company Secretary
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.